Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START: Stimuvax in Stage III NSCLC
NCT00409188Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Jan 2007
- Primary completion
- Apr 2012
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 33
01
Overview
A Phase 3 trial of tecemotide in non-small cell lung cancer (NSCLC), sponsored by EMD Serono. Started Jan 2007; status: completed.
02
Drugs
tecemotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00409188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00409188.